AnaptysBio Inc
ANAB35.160USD
-0.880-2.44%
Market hours （ET）Quotes delayed by 15 min
983.53MMarket Cap
LossP/E TTM
More Details of AnaptysBio Inc Company
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
AnaptysBio Inc Info
Ticker SymbolANAB
Company nameAnaptysBio Inc
IPO dateJan 26, 2017
CEOMr. Daniel R. Faga
Number of employees136
Security typeOrdinary Share
Fiscal year-endJan 26
Address10770 Wateridge Circle, Suite 210
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92121
Phone18583626295
Websitehttps://www.anaptysbio.com/
Ticker SymbolANAB
IPO dateJan 26, 2017
CEOMr. Daniel R. Faga
Company Executives of AnaptysBio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.66K
+13.88%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
6.12K
-34.61%
Mr. Hollings C. Renton
Mr. Hollings C. Renton
Independent Director
Independent Director
4.96K
--
Mr. Dennis M. Mulroy, CPA
Mr. Dennis M. Mulroy, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Paul F. Lizzul, M.D., Ph.D.
Dr. Paul F. Lizzul, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Dennis Fenton, Ph.D.
Dr. Dennis Fenton, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.66K
+13.88%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
6.12K
-34.61%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Oct 8
Updated: Wed, Oct 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
28.15%
Point72 Asset Management, L.P.
8.84%
First Light Asset Management, LLC
7.62%
Morgan Stanley & Co. LLC
5.85%
BlackRock Institutional Trust Company, N.A.
5.52%
Other
44.02%
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
28.15%
Point72 Asset Management, L.P.
8.84%
First Light Asset Management, LLC
7.62%
Morgan Stanley & Co. LLC
5.85%
BlackRock Institutional Trust Company, N.A.
5.52%
Other
44.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
50.35%
Hedge Fund
32.55%
Investment Advisor
29.11%
Research Firm
15.11%
Venture Capital
3.80%
Individual Investor
2.98%
Corporation
2.94%
Bank and Trust
0.28%
Pension Fund
0.12%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
355
36.77M
131.35%
-10.08M
2025Q2
358
40.88M
144.70%
-6.59M
2025Q1
366
43.04M
145.37%
-6.68M
2024Q4
347
37.49M
122.64%
-3.24M
2024Q3
334
34.49M
113.52%
-2.22M
2024Q2
323
30.70M
111.87%
-5.39M
2024Q1
311
29.59M
108.34%
-6.31M
2023Q4
311
30.68M
115.35%
-5.19M
2023Q3
313
31.58M
118.68%
-4.34M
2023Q2
316
31.50M
118.55%
-4.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EcoR1 Capital, LLC
7.88M
28.15%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
2.47M
8.84%
+106.50K
+4.50%
Jun 30, 2025
First Light Asset Management, LLC
2.13M
7.62%
-1.41M
-39.71%
Jul 31, 2025
Morgan Stanley & Co. LLC
1.64M
5.85%
+1.16M
+245.80%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.55M
5.52%
-286.42K
-15.63%
Jun 30, 2025
The Vanguard Group, Inc.
1.53M
5.48%
+20.23K
+1.34%
Jun 30, 2025
Millennium Management LLC
1.43M
5.1%
+1.22M
+601.03%
Sep 16, 2025
Tang Capital Management, LLC
1.33M
4.75%
-214.27K
-13.87%
Jun 30, 2025
UBS Financial Services, Inc.
1.27M
4.55%
+782.23K
+159.55%
Jun 30, 2025
BofA Global Research (US)
1.08M
3.85%
-67.16K
-5.87%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
ALPS Medical Breakthroughs ETF
0.5%
Tema Oncology ETF
0.48%
SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
iShares Micro-Cap ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
Motley Fool Next Index ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.94%
ALPS Medical Breakthroughs ETF
Proportion0.5%
Tema Oncology ETF
Proportion0.48%
SPDR S&P Biotech ETF
Proportion0.24%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.14%
iShares Micro-Cap ETF
Proportion0.13%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares Biotechnology ETF
Proportion0.07%
Motley Fool Next Index ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
